Genelux (GNLX) Capital Expenditures (2022 - 2026)
Genelux (GNLX) posted Capital Expenditures of $921000.0 for Q1 2026, up 111.24% on a QoQ basis from $436000.0 in Q4 2025, and up 2970.0% year-over-year from $30000.0 in Q1 2025.
Powered by 
Analysis
Genelux (GNLX) Capital Expenditures (2022 - 2026) Analysis & Trends
Genelux has reported Capital Expenditures for 5 years, with the latest figure at $921000.0 in Q1 2026.
- On a quarterly basis, Capital Expenditures rose 2970.0% year-over-year to $921000.0 in Q1 2026; TTM through Mar 2026 was $2.0 million, a 422.05% increase from a year earlier, with the FY2025 full-year figure at $1.1 million, up 188.19% from the prior year.
- Capital Expenditures was $921000.0 for Q1 2026 at Genelux, up from $436000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $921000.0 in Q1 2026, with the low at $15000.0 in Q1 2022.
- Average Capital Expenditures over 5 years is $245714.3, with a median of $171500.0 recorded in 2024.
- The sharpest annual moves came in 2024 and 2026: Capital Expenditures tumbled 90.25% in 2024, then soared 2970.0% in 2026.
- Over 5 years, Capital Expenditures stood at $15000.0 in 2022, then jumped by 1520.0% to $243000.0 in 2023, then plunged by 60.49% to $96000.0 in 2024, then jumped by 354.17% to $436000.0 in 2025, then jumped by 111.24% to $921000.0 in 2026.
- The last three Capital Expenditures figures came in at $921000.0 (Q1 2026), $436000.0 (Q4 2025), and $517000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 513.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 140.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 112.20 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 240.20 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 37.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 40.90 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -1.87 Mn |
| 10 | Genelux | 108.17 Mn | 108.17 Mn | - | 921,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 921,000.00 |
| Dec 31, 2025 | 436,000.00 |
| Sep 30, 2025 | 517,000.00 |
| Jun 30, 2025 | 115,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Dec 31, 2024 | 96,000.00 |
| Sep 30, 2024 | 27,000.00 |
| Jun 30, 2024 | 228,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Dec 31, 2023 | 243,000.00 |
| Sep 30, 2023 | 277,000.00 |
| Jun 30, 2023 | 396,000.00 |
| Mar 31, 2023 | 109,000.00 |
| Mar 31, 2022 | 15,000.00 |